AdBio partners’ Post

To really understand the next steps in biomanufacturing and how to partner with a CDMO on the deal structure, watch this video. Vacaville has another 400,000 sq ft available for biotech and biomanufacturing as well as existing partnerships in the community for first and second stage companies in biotech who need biomanufacturing. Solano Community College degrees in biomanufacturing and close ties within the industry provides the right workforce. 27 miles to Sacramento and 50 miles to San Francisco, there are plenty of thought leaders in the industry. Big news is coming with even more opportunities to access local CDMO. #biotechnologyindustry #biotechstartup #cdmo #biomanufacturing

A Monumental Shift in Irish Life Sciences 🌍💼 Chanelle Pharma, Ireland's flagship in generic drug manufacturing, embarks on a new journey with U.K. private equity firm Exponent. In a landmark deal estimated at €300M, this partnership marks a pivotal moment, promising to fuel innovation and growth. With a heritage of excellence and a workforce of over 700, Chanelle Pharma's legacy in human and animal generics is set to soar to new heights. Here's to the future of pharmaceuticals, where tradition meets innovation. 🍀 At Oleson, this development captures our attention for its profound implications on operational excellence and innovation within the life sciences sector. Our commitment to solving business challenges through technical talent resourcing and operational technology consultancy positions us as a pivotal partner in navigating these industry shifts. 🔬 Oleson drives client success,  providing continuity and stability and we are proud to support our clients striding ahead in the face of skill shortages and technological advancements. #LifeSciences #Innovation #Oleson

The August 2024 edition of our Pharma Services: Drug Development BlueBook is now available. Read why C-suite executives and private equity professionals in the health sciences industries turn to our publication for valuation trends, M&A activity, and transaction reporting. Here's a glimpse into the August 2024 edition: 📌Anju was acquired by Valsoft 📌Vion Biosciences announced its acquisition of Ansh Labs 📌Ambrosa Biosciences closed a $16MM Series A Financing, led by Boulder Ventures and BVF Partners Download the full August edition now: https://hubs.li/Q02Vn-HG0 #Insights #MergersAndAcquisitions #PrivateEquity #FinancialNews

Read more about Dr. Taraborelli's journey into the biotech startup space!

Maha Katabi, PhD, CFA, a general partner at one of the leading biotech investment firms (Sofinnova Investments ), has had a busy three months with RayzeBio and Aiolos Bio's M&A exits to Big Pharma, to name a few. She and I spoke this week about deal flow, how clinical-stage biotechs are front and center these days, the appetite for licensing programs out of Chinese drug developers and more. More in our Endpoints News Q&A: #biotech #investing #pharma #biomedicalresearch #mergersandacquisitions #chinabiotech

✨ ICYMI: Endpoints News speaks with our General Partner, Maha Katabi, PhD, CFA about the recent market activity and thoughts on IPOs, M&As, and deal flow. “Maha Katabi has had a great three months. The Sofinnova General Partner has been in the boardroom of two recent M&A exits: radiopharmaceuticals maker RayzeBio sold to Bristol Myers Squibb, and asthma startup Aiolos Bio, to GSK." Read the full Q&A here: https://lnkd.in/gEXCPXem

While M&A activity in the #LifeSciences sector has slowed slightly since the surge in the run up to and during JPM, there has been some interesting activity during February nonetheless. Here's a quick take from Ross McNaughton and me.   ➡ Weight loss and metabolic disease remains in the spotlight with the Novo/Catalent ($16.5bn) deal taking the headlines, with Novo looking to shore up its production lines for Wegovy.   ➡ Novartis continued its spending spree, with its acquisition of MorphoSys ($2.7bn), with their CEO commenting that they were looking to focus on "bolt-on acquisitions" sub-$5bn; sizable, but not blockbuster M&A, and suggestive of a general trend across the industry of shoring up pipelines.   ➡ Pharma's focus on later stage assets was also in play with the Gilead/CymaBay ($4.3bn) deal, with CymaBay's drug Seldelpar already through phase 3 and accepted by the FDA for priority review   ➡ Feb also saw a stark reminder of the importance of regulatory scrutiny and use of patents in market competition (cf also Pfizer/Seagen; Amgen/Horizon) with the FTC calling on the Abbvie/Cerevel deal for second stage review   ➡ #AnimalHealth also had its deal in the spotlight with Merck acquiring Elanco for $1.3bn in cash. An area of increasing interest for companies in this pace, and following also Zoetis's acquisition of PetMedix in the UK last year.   In the private markets, great to see some new funds raised by Scion Life Sciences ($310m) and ORI Capital ($260m), coming on the back of the Goldman Sachs' West Street Life Sciences $650M fund in January. Here at Taylor Wessing, we’re definitely seeing positive developments in the #venturecapital market with some great funding rounds closing out. #lifesciences #mergersandacquisitions Activate to view larger image,

C-suite leaders from Eli Lilly and Company, Roche and Johnson & Johnson spoke at a Citeline-sponsored panel at Swiss Biotech Day in Basel and offered encouragement to start-ups trying to negotiate the tricky financial landscape. Biotech financing has been under pressure for a couple of years, forcing companies to work harder to advance their pipelines. Forging partnerships with big pharma is more important than ever, and this article provides biotech leaders with insider pointers on how to approach this. Access it now: https://ow.ly/UMwb50RxgTs. #BiotechLeaders #PharmaPartnerships #BiotechFinancing #HealthcareInnovation #CLevelPanel #SwissBiotechDay

📄 [Press Release] – MaaT Pharma is proud to announce the successful completion of its Global Offering of 19.2 Million Euros ▪ Support from historical investors Bpifrance, Seventure Partners, Biocodex, and from the management of the Company ▪ 70% of new retail investors previously non-shareholders joined us, showcasing a strong influx of new support, with a total investment of €0.9 million ▪ Financing will enable the Company to extend its cash runway through early Q1 2025 ▪ The net proceeds from the Primary Offering will be used to fund the company’s R&D activities, covering completion of the Phase 3 trial for MaaT013 in Europe, including top-line results/primary endpoint in mid Q4 2024, continuing the pipeline development, including the initiation of Phase 3 trial activities for MaaT013 in the US and the broadening of the Phase 2b trial with MaaT033 across Europe and for working capital and other general corporate purposes, including repayment of current debts. 👉 Read the press release here: https://lnkd.in/efFj8Ube

Last week, I had the privilege of leading the inaugural BIO-sponsored “Commercial Readiness from Preclinical to 1st Launch: The First Time CEO’s Playbook” at the BIO CEO & Investor Conference in NYC.   The course is designed for 1st time biotech CEOs/CBO’s /CFO's. The first section is focused on three stages of drug development and highlights how and where the lack of essential commercial expertise & insights leads to: ·    Lost value of the lead asset and/or portfolio ·    Development of an asset with little to no commercial value ·    Failed commercial launches   Any or all of these three lead to diminished investor interest.    The course also highlights how/why most emerging company commercial launches fail.   It then provides the CEO’s/CBO’s/CFO's with the critical commercial knowledge, tools and insights required for successful drug development through each of the three stages up to 1st launch.    There is a fundamental gap at emerging biotech companies understanding how/where commercial expertise needs to be involved and my mission is to change that and fill that cavernous gap to enable far more commercial success.    If you are a first-time biotech CEO, navigating early development from Preclinical to Phase 3 (pre-data) without a “Commercial Compass”, reach out to me at russ@bridge1.net or 415-307-0774. I will help you find your company’s Commercial True North. www.bridge1.net #commercialization #CEO #COO #CFO #CBO #commerciallaunch #emergingbiotech #biotech #pharma #preclinical #firsttimeceo #newceo #drugdevelopment